Shasun Chemicals cons net profit of Rs 4.88cr in Q1FY08

Published on Tue, Jul 24, 2007 at 18:29 |  Source : Moneycontrol.com

Updated at Tue, Jul 24, 2007 at 20:58  

4256 Investors following Shasun Pharma. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Shasun Chemicals and Drugs Ltd ., a leading pharma company focused on providing services of research and manufacture of finished dosage, APIs (Active Pharmaceutical Ingredients) and intermediates to global pharma, posted a 35% per cent growth in consolidated revenue at Rs 205.64 crore for the quarter ending June 30, 2007 (Q1FY08) compared to Rs 152.50 crore in Q1 FY07. Consolidated net profit stood at Rs. 4.88 crore compared to Rs. 7.47 crore in Q1FY07. EBITDA for the Q1 was Rs. 16.66 crore as against Rs.16.63 crore in the previous years' corresponding quarter; registering a growth of 0.19 percent.  

 

On a standalone basis, the Income from Operations grew by 2.80 per cent to Rs.102.25 crore compared to Rs. 99.46 crore in the corresponding quarter of last year. The net profit stood at Rs 1.66 crore for the Q1FY08 as against Rs.6.17 crore in Q1 FY07. The lower profit was mainly due to lower Nizatidine sales for the quarter.  The CRAM business recorded revenue of Rs 10 crore this quarter as against Rs 6 crore in Q1FY07.

 

Meanwhile, the wholly owned subsidiary Shasun Pharma Solutions Ltd. (SPSL) posted sale revenue of GBP 12.8 mn and PAT of GBP 0.295 mn which includes release of negative goodwill of GBP 0.278 mn. 

 

Sourced From: Adfactors Public Relations Pvt Ltd 

  

More on Moneycontrol

Trending News

Business News

Apple rushing to finalize apps for iPad 3 announcement
Forget the IIP: there's free cash oozing out of every pore "Forget the IIP: there's free cash oozing out of every pore "

DLF Says Macro Environment Unfavourable W/High Comm & Labour Inflation

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com